...
首页> 外文期刊>ACS Omega >Synthesis and Postpolymerization Modification of Fluorine-End-Labeled Poly(Pentafluorophenyl Methacrylate) Obtained via RAFT Polymerization
【24h】

Synthesis and Postpolymerization Modification of Fluorine-End-Labeled Poly(Pentafluorophenyl Methacrylate) Obtained via RAFT Polymerization

机译:通过RAFT聚合获得的含氟末端标签的聚(五氟苯基甲基丙烯酸甲酯)的合成和后聚合改性

获取原文

摘要

Chain-end-labeled polymers are interesting for a range of applications. In polymer nanomedicine, chain-end-labeled polymers are useful to study and help understand cellular internalization and intracellular trafficking processes. The recent advent of fluorescent label-free techniques, such as nanoscale secondary ion mass spectrometry (NanoSIMS), provides access to high-resolution intracellular mapping that can complement information obtained using fluorescent-labeled materials and confocal microscopy and flow cytometry. Using poly(N-(2-hydroxypropyl)methacrylamide) (PHPMA) as a prototypical polymer nanomedicine, this paper presents a synthetic strategy to polymers that contain trace element labels, such as fluorine, which can be used for NanoSIMS analysis. The strategy presented in this paper is based on reversible addition fragmentation chain transfer (RAFT) polymerization of pentafluorophenyl methacrylate (PFMA) mediated by two novel chain-transfer agents (CTAs), which contain either one (α) or two (α,ω) fluorine labels. In the first part of this study, via a number of polymerization experiments, the polymerization properties of the fluorinated RAFT CTAs were established. 19F NMR spectroscopy revealed that these fluorinated RAFT agents possess unique spectral signatures, which allow to directly monitor RAFT agent conversion and measure end-group fidelity. Comparison with 4-cyanopentanoic acid dithiobenzoate, which is a standard CTA for the RAFT polymerization of PFMA, revealed that the introduction of one or two fluorine labels does not significantly affect the polymerization properties of the CTA. In the last part of this paper, a proof-of-concept study is presented that demonstrates the feasibility of the fluorine-labeled poly(pentafluorophenyl methacrylate) polymers as platforms for the postpolymerization modification to generate PHPMA-based polymer nanomedicines.
机译:链端标记的聚合物对于一系列应用很有趣。在聚合物纳米医学中,链端标记的聚合物可用于研究和帮助理解细胞内在化和细胞内运输过程。无荧光标记技术的最新出现,例如纳米级二次离子质谱(NanoSIMS),提供了高分辨率的细胞内作图的方法,可以对使用荧光标记的材料以及共聚焦显微镜和流式细胞术获得的信息进行补充。本文使用聚(N-(2-羟丙基)甲基丙烯酰胺)(PHPMA)作为典型的聚合物纳米药物,为包含微量元素标记(例如氟)的聚合物提出了一种合成策略,可用于NanoSIMS分析。本文提出的策略基于五种甲基丙烯酸五氟苯酯(PFMA)的可逆加成断裂链转移(RAFT)聚合,该聚合由两种新型链转移剂(CTA)介导,其中两种或两种包含一个(α)或两个(α,ω)氟标签。在本研究的第一部分中,通过许多聚合实验,确定了氟化RAFT CTA的聚合性能。 19F NMR光谱显示,这些氟化的RAFT试剂具有独特的光谱特征,可直接监控RAFT试剂的转化并测量端基保真度。与PFMA RAFT聚合的标准CTA 4-氰基戊酸二硫代苯甲酸酯的比较表明,引入一个或两个氟标记不会显着影响CTA的聚合性能。在本文的最后一部分中,进行了概念验证研究,该研究证明了氟标记的聚(甲基丙烯酸五氟苯基酯)聚合物作为平台进行后聚合修饰以生成基于PHPMA的聚合物纳米药物的可行性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号